PT3157531T - Métodos e composições para estimulação do sistema enteroendócrino intestinal para tratamento de doenças ou condições relacionadas com o mesmo - Google Patents
Métodos e composições para estimulação do sistema enteroendócrino intestinal para tratamento de doenças ou condições relacionadas com o mesmoInfo
- Publication number
- PT3157531T PT3157531T PT158117143T PT15811714T PT3157531T PT 3157531 T PT3157531 T PT 3157531T PT 158117143 T PT158117143 T PT 158117143T PT 15811714 T PT15811714 T PT 15811714T PT 3157531 T PT3157531 T PT 3157531T
- Authority
- PT
- Portugal
- Prior art keywords
- stimulation
- compositions
- methods
- same
- treating diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015657P | 2014-06-23 | 2014-06-23 | |
| US14/329,627 US10040817B2 (en) | 2013-10-03 | 2014-07-11 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3157531T true PT3157531T (pt) | 2021-07-01 |
Family
ID=54869043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158117143T PT3157531T (pt) | 2014-06-23 | 2015-06-22 | Métodos e composições para estimulação do sistema enteroendócrino intestinal para tratamento de doenças ou condições relacionadas com o mesmo |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US10040817B2 (enExample) |
| EP (1) | EP3157531B1 (enExample) |
| JP (2) | JP6692300B2 (enExample) |
| CN (2) | CN106535902B (enExample) |
| BR (1) | BR112016029917A2 (enExample) |
| CA (1) | CA2951720C (enExample) |
| CY (1) | CY1124554T1 (enExample) |
| DK (1) | DK3157531T3 (enExample) |
| ES (1) | ES2878077T3 (enExample) |
| HR (1) | HRP20211005T1 (enExample) |
| HU (1) | HUE054828T2 (enExample) |
| LT (1) | LT3157531T (enExample) |
| MX (2) | MX382442B (enExample) |
| PL (1) | PL3157531T3 (enExample) |
| PT (1) | PT3157531T (enExample) |
| RS (1) | RS62064B1 (enExample) |
| SI (1) | SI3157531T1 (enExample) |
| SM (1) | SMT202100373T1 (enExample) |
| WO (1) | WO2015200195A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10040817B2 (en) * | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
| WO2018222665A1 (en) * | 2017-05-31 | 2018-12-06 | Enterin Laboratories, Inc. | Methods and compositions for preventing or treating inflammatory diseases |
| US11083735B2 (en) * | 2017-09-08 | 2021-08-10 | Enterin, Inc. | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions |
| US11066438B2 (en) | 2017-10-30 | 2021-07-20 | Enterin, Inc. | Squalamine solid forms and methods of making the same |
| CA3094977A1 (en) * | 2018-03-27 | 2019-10-03 | Enterin, Inc. | Methods and compositions for treating hallucinations and conditions related to the same |
| SG11202012343TA (en) * | 2018-06-13 | 2021-01-28 | Enterin Inc | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
| EP3829587A4 (en) * | 2018-08-03 | 2022-07-20 | Enterin, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS |
| US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
| US20210315907A1 (en) * | 2018-08-03 | 2021-10-14 | Enterin, Inc, | Compositions and methods for treating brain-gut disorders |
| EP3829537A4 (en) * | 2018-08-03 | 2022-09-21 | Enterin, Inc. | LOW DOSAGE INTRANASAL DOSAGE FORMS OF AMINOSTEROL AND METHODS OF USE THEREOF |
| US20230125585A1 (en) * | 2019-08-02 | 2023-04-27 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
| DE69412596T2 (de) | 1993-03-10 | 1999-03-04 | Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. | Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel |
| US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
| US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| AU3512595A (en) | 1994-09-13 | 1996-03-29 | Magainin Pharmaceuticals, Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| US5834453A (en) | 1995-05-30 | 1998-11-10 | Lehigh University | Methods for the manufacture and use of antimicrobial sterol conjugates |
| US5795885A (en) | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
| ES2216049T3 (es) | 1995-06-07 | 2004-10-16 | Genaera Corporation | Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos. |
| US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
| US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US5840936A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
| US5994336A (en) | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
| US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5744453A (en) | 1996-01-05 | 1998-04-28 | Mintz; Clifford S. | Polyamine conjugates for treatment of infection |
| US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| PT910382E (pt) | 1996-04-26 | 2003-10-31 | Genaera Corp | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
| US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
| CA2255856C (en) | 1996-05-17 | 2008-05-13 | Magainin Pharmaceuticals Inc. | Therapeutic uses for an aminosterol compound |
| AU5194998A (en) | 1996-11-01 | 1998-05-29 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and uses therefor |
| ATE375359T1 (de) | 1998-08-12 | 2007-10-15 | Genaera Corp | Aminosterolderivate und ihre verwendungen |
| US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| EP1358200A4 (en) * | 2000-10-06 | 2005-07-20 | Xenoport Inc | COMPOUNDS DERIVED FROM GALLENIC ACID TO IMPROVE THE ORAL ABSORPTION AND SYSTEMIC BIOVERABILITY OF MEDICAMENTS |
| US6900192B2 (en) | 2000-10-06 | 2005-05-31 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| TR201903603T4 (tr) * | 2002-01-28 | 2019-04-22 | Kyowa Hakko Kogyo Kk | Hareket bozukluklarının tedavisinde kullanım için A2A reseptörü antagonistleri. |
| AU2003298514A1 (en) | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US7981876B2 (en) | 2005-04-25 | 2011-07-19 | Ohr Pharmaceuticals, Inc. | Polymorphic and amorphous salt forms of squalamine dilactate |
| WO2009032321A2 (en) | 2007-09-06 | 2009-03-12 | Genaera Corporation | A method for treating diabetes |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| US8729058B2 (en) | 2009-10-27 | 2014-05-20 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| US8623416B2 (en) | 2009-11-25 | 2014-01-07 | Michael Zasloff | Formulations comprising aminosterols |
| JP6165843B2 (ja) | 2012-04-20 | 2017-07-19 | オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． | Ｐｔｐ１ｂ関連疾患の処置のためのアミノステロイド化合物 |
| CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
| EP2934543B1 (en) | 2012-12-20 | 2018-10-31 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2014
- 2014-07-11 US US14/329,627 patent/US10040817B2/en active Active
-
2015
- 2015-06-22 CA CA2951720A patent/CA2951720C/en active Active
- 2015-06-22 CN CN201580033333.7A patent/CN106535902B/zh active Active
- 2015-06-22 MX MX2016017368A patent/MX382442B/es unknown
- 2015-06-22 PT PT158117143T patent/PT3157531T/pt unknown
- 2015-06-22 LT LTEP15811714.3T patent/LT3157531T/lt unknown
- 2015-06-22 BR BR112016029917A patent/BR112016029917A2/pt not_active Application Discontinuation
- 2015-06-22 JP JP2016574402A patent/JP6692300B2/ja active Active
- 2015-06-22 WO PCT/US2015/036935 patent/WO2015200195A1/en not_active Ceased
- 2015-06-22 ES ES15811714T patent/ES2878077T3/es active Active
- 2015-06-22 PL PL15811714T patent/PL3157531T3/pl unknown
- 2015-06-22 DK DK15811714.3T patent/DK3157531T3/da active
- 2015-06-22 HR HRP20211005TT patent/HRP20211005T1/hr unknown
- 2015-06-22 HU HUE15811714A patent/HUE054828T2/hu unknown
- 2015-06-22 RS RS20210819A patent/RS62064B1/sr unknown
- 2015-06-22 EP EP15811714.3A patent/EP3157531B1/en active Active
- 2015-06-22 SM SM20210373T patent/SMT202100373T1/it unknown
- 2015-06-22 CN CN202110489234.7A patent/CN113559108A/zh active Pending
- 2015-06-22 SI SI201531637T patent/SI3157531T1/sl unknown
-
2016
- 2016-12-20 MX MX2021005489A patent/MX2021005489A/es unknown
-
2017
- 2017-05-24 US US15/604,489 patent/US10208079B2/en active Active
- 2017-05-24 US US15/604,452 patent/US10196420B2/en active Active
- 2017-05-24 US US15/604,527 patent/US10208080B2/en active Active
-
2018
- 2018-07-13 US US16/035,537 patent/US10633413B2/en active Active
- 2018-07-18 US US16/039,294 patent/US11440936B2/en active Active
- 2018-12-13 US US16/219,879 patent/US20190185513A1/en not_active Abandoned
- 2018-12-13 US US16/219,848 patent/US10975116B2/en active Active
- 2018-12-14 US US16/220,860 patent/US20190194244A1/en not_active Abandoned
-
2020
- 2020-01-21 JP JP2020007206A patent/JP7010979B2/ja active Active
-
2021
- 2021-06-28 CY CY20211100573T patent/CY1124554T1/el unknown
-
2022
- 2022-04-01 US US17/711,891 patent/US20220220148A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
| PL3349783T3 (pl) | Kompozycje i sposoby do leczenia chorób | |
| PL3157531T3 (pl) | Sposoby i kompozycje do stymulacji jelitowego układu enteroendokrynnego w leczeniu chorób lub stanów związanych z tym układem | |
| IL323562A (en) | Methods for treating inflammatory diseases | |
| IL253244B1 (en) | Methods for treating retinal diseases | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| IL285003A (en) | Treatment of episode disorders | |
| IL257561A (en) | Methods for treating inflammatory diseases | |
| HUE055913T2 (hu) | Módszerek és készítmények a glioblastoma diagnosztizálására és kezelésére | |
| GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
| ZA201705877B (en) | Method of treating diseases | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
| IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
| IL253847A0 (en) | Methods of treating diseases | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| IL251135A0 (en) | A method for the synthesis of hydroxy-triglycerides and their use for the prevention and treatment of diseases | |
| IL257689A (en) | Pharmacological preparations and methods for the treatment of diseases associated with hypoxia | |
| HK1236807A1 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
| GB201516303D0 (en) | Compositions and methods relating to the treatment of diseases | |
| AP2016009662A0 (en) | Combination of taurine and racemethionine for treatment of liver diseases | |
| GB201516437D0 (en) | Compositions and methods relating to the treatment of disease | |
| EP3223828A4 (en) | Methods for the treatment and prevention of asbestos-related diseases | |
| GB201414023D0 (en) | Treatment of autoimmune diseases |